Prevention of early asthma in childhood trial with pranlukast in Mie; PROACT-Mie

Prevention of early asthma in childhood trial with pranlukast in Mie; PROACT-Mie - Early intervention with pranlukast for recurrent wheeze in infants

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001918

Enrollment

100

Registered

2009-05-01

Start date

2005-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wheezing syndrome in infants

Interventions

pranlukast and as-needed beta agonists as-needed beta agonists

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: recurrent wheeze more than once

Exclusion criteria

Exclusion criteria: Wheezing due to congenital anatomical anomaly, wheezing due to mediatinal neoplasm, croup syndrome, foreign body in the airways, heart diseases, pneumonia, tuberculosis, administration of leukotriene receptor antagonists, cromolyns, anti-histamines, severe liver/renal/heart diseases

Design outcomes

Primary

Measure	Time frame
wheezing episodes during and after treatment with pranlukast	—

Secondary

Measure	Time frame
rate of dropout because of persistent asthma symptoms	—

Countries

Japan

Contacts

Public ContactYuki Yamamoto

Mie National Hospital Department of clinical trials

fujisawa@mie-m.hosp.go.jp059-245-6355

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026